Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model.

Autor:	Blouin M; STP Laboratory, Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada.; Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada., Métras MÉ; Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada.; Department of Pharmacy, Centre Hospitalier Universitaire Sainte-Justine, Montréal (QC), Canada; and., El Hassani M; STP Laboratory, Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada.; Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada., Yaliniz A; STP Laboratory, Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada.; Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada., Marsot A; STP Laboratory, Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada.; Faculty of Pharmacy, Université de Montréal, Montréal (QC), Canada.; Research Center, Centre Hospitalier Universitaire Sainte-Justine, Montréal (QC), Canada.
Jazyk:	angličtina
Zdroj:	Therapeutic drug monitoring [Ther Drug Monit] 2024 Jun 06. Date of Electronic Publication: 2024 Jun 06.
DOI:	10.1097/FTD.0000000000001226
Abstrakt:	Background: Vancomycin therapeutic monitoring guidelines were revised in March 2020, and a population pharmacokinetics-guided Bayesian approach to estimate the 24-hour area under the concentration-time curve to the minimum inhibitory concentration ratio has since been recommended instead of trough concentrations. To comply with these latest guidelines, we evaluated published population pharmacokinetic models of vancomycin using an external dataset of neonatal patients and selected the most predictive model to develop a new initial dosing regimen. Methods: The models were identified from the literature and tested using a retrospective dataset of Canadian neonates. Their predictive performance was assessed using prediction- and simulation-based diagnostics. Monte Carlo simulations were performed to develop the initial dosing regimen with the highest probability of therapeutic target attainment. Results: A total of 144 vancomycin concentrations were derived from 63 neonates in the external population. Five of the 28 models retained for evaluation were found predictive with a bias of 15% and an imprecision of 30%. Overall, the Grimsley and Thomson model performed best, with a bias of -0.8% and an imprecision of 20.9%; therefore, it was applied in the simulations. A novel initial dosing regimen of 15 mg/kg, followed by 11 mg/kg every 8 hours should favor therapeutic target attainment. Conclusions: A predictive population pharmacokinetic model of vancomycin was identified after an external evaluation and used to recommend a novel initial dosing regimen. The implementation of these model-based tools may guide physicians in selecting the most appropriate initial vancomycin dose, leading to improved clinical outcomes. Competing Interests: Conflicts of interest statement: The authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu